What does Ki-67 mean on a pathology report
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Ki-67 on Your Pathology Report
Ki-67 is a protein that measures how fast cancer cells are dividing and growing. Think of it as a "proliferation index" — essentially a snapshot of how active your cancer cells are at the cellular level.
How It Works
When pathologists examine your cancer tissue under a microscope, they use special stains to identify which cells are actively dividing. Ki-67 is a marker that appears in cells that are in the process of reproducing. The pathologist counts what percentage of cancer cells show this marker.
What the Percentage Means
Ki-67 is reported as a percentage (for example, "Ki-67: 20%"):
- Low Ki-67 (typically <10-15%): Cancer cells are dividing slowly — generally associated with slower-growing cancers
- Intermediate Ki-67 (15-30%): Moderate growth rate
- High Ki-67 (>30%): Cancer cells are dividing rapidly — suggests more aggressive behavior
Why Doctors Care About This
According to NCCN Guidelines and ASCO recommendations, Ki-67 helps oncologists:
- Assess how aggressive your cancer is
- Predict how the cancer might behave
- Help guide treatment decisions (particularly in breast cancer, where it influences hormone therapy vs. chemotherapy choices)
- Estimate prognosis alongside other factors
Important Context
Ki-67 is one piece of information among many. Your doctor considers it alongside:
- Tumor grade and stage
- Hormone receptor status (ER/PR)
- HER2 status
- Other biomarkers specific to your cancer type
Questions to Ask Your Doctor
- What is my specific Ki-67 percentage, and what does that mean for my cancer?
- How does my Ki-67 result influence your treatment recommendations?
- Are there other markers you're considering alongside Ki-67 in my case?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with diagnosis for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2